(A) Schematic diagram of intradermal administration of agomir-NC (5 nmol) or agomir-210 (5 nmol) on days 0, 1, 2, and 3 during the application of IMQ in mice (BALB/c). Three mice in each group were sacrificed on days 4, 7, 10, and 14 to conduct experiments. (B) Phenotypic presentation and H&E staining of lesional skin from mice injected with agomir-NC and agomir-210. Scale bars: 100 μm. (C) The miR-210 expression in splenic CD4⁺ T cells from agomir-NC–treated (n = 6) or agomir-210–treated mice (n = 6). (D) The size of spleens of mice in A. (E) PASI scores of mice in A (n = 6). (F and G) Acanthosis and dermal cellular infiltrates were quantified for mice treated with agomir-NC (n = 6) or agomir-210 (n = 6). For all measurements in G, the median number of specifically stained dermal nucleated cells was counted in 3 high-power fields per section. (H) The mRNA levels of Il17a, Il17f, Ifng, and Il4 in splenic CD4⁺ T cells from agomir-NC–treated (n = 3) or agomir-210–treated mice (n = 3). Data (D–H) were obtained from agomir-NC– or agomir-210–treated mice on the seventh day. Data (B–H) are representative of at least 3 independent experiments with 3 to 6 samples per group in each. Data represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant. Two-tailed unpaired Student’s t test (C and E–H) was used.